NKCFO LLC’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

NKCFO LLC’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,800	Closed	-$111K	–	108
2022 Q3	$111K	Sell	1,800 -905	-33%	-$63.2K	0.05%	62
2022 Q2	$216K	Buy	2,705 +1,800	+199%	+$170K	0.08%	51
2022 Q1	$95K	Buy	905 +265	+41%	+$25.8K	0.03%	94
2021 Q4	$69K	Buy	+640	New	+$69.8K	0.02%	94
2021 Q3	–	Sell	-2,200	Closed	-$206K	–	118
2021 Q2	$206K	Buy	+2,200	New	+$202K	0.07%	80
2020 Q4	–	Sell	-4,650	Closed	-$361K	–	136
2020 Q3	$361K	Sell	4,650 -4,650	-50%	-$320K	0.16%	27
2020 Q2	$517K	Hold	9,300	–	–	0.35%	19
2020 Q1	$275K	Hold	9,300	–	–	0.26%	30
2019 Q4	$337K	Hold	9,300	–	–	0.25%	31
2019 Q3	$253K	Hold	9,300	–	–	0.19%	52
2019 Q2	$224K	Hold	9,300	–	–	0.17%	54
2019 Q1	$246K	Buy	+9,300	New	+$220K	0.17%	60

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

NKCFO LLC's HZNP Position: Q4 2022 in Review

NKCFO LLC sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2022, closing a stake of 1,800 shares — an estimated $111K sold.

NKCFO LLC first reported a position in HZNP in Q1 2019 and held it in 12 quarters. The position peaked at $517K in Q2 2020. 615 funds tracked by Wall St. Rank hold HZNP as of Q4 2022.

NKCFO LLC reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2022 after selling out during the quarter.
NKCFO LLC sold 1,800 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2022, an estimated $111K.
NKCFO LLC first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2019 and held it in 12 quarters.
NKCFO LLC's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $517K in Q2 2020.
615 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2022.

Based on NKCFO LLC's 13F filing for Q4 2022, filed 26 Jan 2023.